Quest Diagnostics (DGX) continues its strong growth trajectory in the diagnostic space as indicated by several factors. Recent acquisitions such as LifeLabs and University Hospitals' Outreach Laboratory Services indicate a strategic expansion. Other acquisitions include Select PathAI Diagnostics' Lab Assets, which may pave way for the advancement in cancer diagnosis using AI and digital pathology. Despite certain unloading of shares by insider Karthik Kuppusamy, the company's stock performs strong, hitting a yearly high of $155.5. The organization also raised its Q2 2024 financial guidance illustrating a robust financial performance consistently aligning with analysts' EPS projections. DGX is making strides in strategical partnerships, one with BD for companion diagnostics and the other with Instacart to confront food insecurity in the US. The firm is also credited with being a top workplace for disability inclusion, seven years running. These strategies underline DGX’s continuing growth and influence in the diagnostics space, moving forward.
Quest Diagnostics DGX News Analytics from Tue, 24 Oct 2023 07:00:00 GMT to Fri, 30 Aug 2024 15:02:54 GMT -
Rating 8
- Innovation 6
- Information 9
- Rumor 1
